Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.
J Nephrol. 2009 Nov-Dec;22(6):708-15.
A number of studies have identified transforming growth factor-beta (TGF-beta) as a critical factor in renal diseases such as glomerulosclerosis and mesangioproliferative glomerulonephritis. TGF-beta stimulates proliferation of mesangial cells, production of extracellular matrix components and induces epithelial-mesenchymal transformation in renal tissue, which plays a critical role in the pathogenesis of renal injury. Thus, TGF-beta is a treatment target in renal diseases. However, progressive renal diseases cannot be cured with present medical technologies. We have developed ribozymes and a novel gene silencer pyrrole-imidazole polyamide targeted to TGF-beta that effectively ameliorate renal injury in hypertensive rats.
许多研究已经确定转化生长因子-β（TGF-β）是肾小球硬化和系膜增生性肾小球肾炎等肾脏疾病的关键因素。TGF-β刺激系膜细胞增殖、细胞外基质成分的产生，并诱导肾脏组织中的上皮-间充质转化，这在肾脏损伤的发病机制中起关键作用。因此，TGF-β是肾脏疾病的治疗靶点。然而，目前的医疗技术并不能治愈进行性肾脏疾病。我们已经开发了针对 TGF-β的核酶和一种新型基因沉默剂吡咯-咪唑聚酰胺，它们可有效改善高血压大鼠的肾脏损伤。
